TY - JOUR AB - Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective medications for managing obesity and related metabolic complications. However, their use presents specific challenges when obesity is coexisting with eating disorders. In such cases, the appetite-suppressing effects of GLP-1RAs could potentially exacerbate behaviors like dietary restriction and dietary restraint, two behavioral patterns that help sustain eating disorder psychopathology, thus complicating treatment for these disorders. Because of these concerns, it is essential for clinicians to screen for eating disorders before prescribing GLP-1RAs in individuals with overweight or obesity. Their use is currently contraindicated for patients with atypical anorexia nervosa, bulimia nervosa, or subthreshold bulimia nervosa, as GLP-1RAs could worsen the restrictive eating behaviors common in these conditions. Although some emerging research suggests that GLP-1RAs might reduce binge-eating episodes, there is not yet enough evidence to support their use specifically for treating binge-eating disorder (BED) and its associated psychopathology. According to new recommendations from cognitive behavior therapy for BED, GLP-1RAs may be cautiously considered in patients with clinical obesity who do not overvalue shape and weight, have no history of anorexia nervosa or bulimia nervosa, and who have already made progress in adopting regular eating patterns and reducing binge-eating episodes. AD - rdalleg@gmail.com AU - Dalle Grave, R. DA - 18-11-2024 DO - 10.32044/ijedo.2024.02 L1 - internal-pdf://2034039617/202402.ris LA - English M3 - Original article PY - 2024 SE - 15 SN - 2612-6354 SP - 15-24 ST - Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders T2 - IJEDO TI - Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders VL - 6 ID - 16 ER -